NDA 022268 · Novartis
Coartem
Artemether, Lumefantrine · Oral · Antimalarial
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Aug 5, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Apr 7, 2009
Approved uses
1
Original approval plus efficacy supplements
Registered trials
223
54 Phase 3, 8 recruiting
FAERS reports
198
174 serious, 23 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 26, 2026.
Coartem Tablets are indicated for treatment of acute, uncomplicated malaria infections due to Plasmodium falciparum (P. falciparum) in patients 2 months of age and older with a bodyweight of 5 kg and above. Coartem Tablets have been shown to be effective in geographical regions where resistance to chloroquine has been reported [see Clinical Studies (14.1)] . Limitations of Use : Coartem Tablets are not approved for patients with severe or complicated P. falciparum malaria. Coartem Tablets are not approved for the prevention of malaria. Coartem Tablets are a combination of artemether and lumefantrine, both antimalarials, indicated for treatment of acute, uncomplicated malaria infections due to Plasmodium falciparum (P. falciparum) in patients 2 months of age and older with a bodyweight of 5 kg and above. ( 1 ) Coartem Tablets have been shown to be effective in geographical regions where resistance to chloroquine has been reported. ( 1 ) Limitations of Use: ( 1 ) Coartem Tablets are not approved for patients with severe or complicated P. falciparum malaria . Coartem Tablets are not approved for the prevention of malaria.
Mechanism: Coartem Tablets, a fixed dose combination of artemether and lumefantrine in the ratio of 1:6, is an antimalarial agent [see Microbiology (12.4)] .
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 7, 2009 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
- COARTEM · ARTEMETHER 20MG; LUMEFANTRINE 120MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Artemether" as an intervention, any sponsor and status, largest first.
- Targeted Active Case Detection Among High Risk Populations in Southern Lao Peoples Democratic RepublicPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT03783299 · 39,968 participants · Start Nov 28, 2017 · Primary completion Nov 30, 2018
Drug: Artemether-lumefantrine; Primaquine Phosphate · For: Plasmodium Falciparum Malaria
Sites: Vientiane, Laos
- Reducing the Burden of Malaria by Targeting Hotspots of Malaria TransmissionPivotal-lookingCompleted
Radboud University Medical CenterAcademic, hospital or other
NCT01575613 · 17,506 participants · Start Apr 2012 · Primary completion Nov 2012
Drug: Artemether-lumefantrine combination; Bacillus thuringiensis and 2 more · For: Malaria
Sites: Rachuonyo District, Kenya
- A Community Setting Study of Malaria After Systematic Treatment of Symptomatic Carriers of P. Falciparum With COA566 (Coartem®)Pivotal-lookingCompleted
NovartisNovartis (NVS)
NCT01256658 · 14,075 participants · Start Nov 2010 · Primary completion Jul 2012
Drug: COA566 · For: Malaria
Sites: Ouagadougou, Burkina Faso; Burkina Faso, Burkina Faso · 3 sites in all
- Dihydroartemisinin-piperaquine for Seasonal Malaria Chemoprophylaxis in TanzaniaPivotal-lookingCompleted
Richard MwaisweloGovernment (non-federal)
NCT05874869 · 13,800 participants · Start Jul 1, 2020 · Primary completion Jun 30, 2021
Drug: Dihydroartemisinin-piperaquine · For: Malaria; Chemoprophylaxis; Underfive Children
Sites: Dar es Salaam, Tanzania
- Targeted Antimalarial Drug Administration for Seasonal Migrant Populations in Amhara Region, EthiopiaPivotal-lookingActive, not recruiting
PATHAcademic, hospital or other
NCT06516042 · 10,350 participants (planned) · Start Aug 21, 2024 · Primary completion Jan 24, 2025
Drug: Dihydroartemisinin-piperaquine · For: Plasmodium Falciparum; Malaria
Sites: Gonder, Ethiopia
- Community-led Responses for Elimination: Controlled Trial of Reactive Case Detection Versus Reactive Drug AdministrationPivotal-lookingCompleted
PATHAcademic, hospital or other
NCT02654912 · 8,682 participants · Start Feb 2016 · Primary completion Jun 2020
Drug: Reactive Focal Drug Administration · For: Malaria
Sites: Choma, Zambia
- Assessment of Use of Rapid Diagnostic Testing in the Context of Home Management With ACTsPivotal-lookingCompleted
Mbarara University of Science and TechnologyAcademic, hospital or other
NCT00720811 · 6,456 participants · Start Oct 2009 · Primary completion Jan 2012
Drug: Artemether-lumefantrine combination; amoxycillin and 2 more · For: Malaria; Pneumonia
Sites: Saponé, Burkina Faso; Kassane, Ghana; Iganga, Uganda · 4 sites in all
- The Impact RTS,S/AS01 Vaccine in School Aged Children RTS,S/AS01 Malaria Vaccine in School Aged ChildrenPivotal-lookingStatus unknown
Kamuzu University of Health SciencesAcademic, hospital or other
NCT06424002 · 5,400 participants (planned) · Start Jun 1, 2024 · Primary completion Dec 20, 2024
Drug: Mosquirixs; artemether-lumefantrine · For: Malaria,Falciparum
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pyrexia22
- vomiting18
- dyspnoea17
- asthenia16
- malaise13
- malaria13
- drug ineffective12
- maternal exposure during pregnancy11
- headache10
- anaemia9
- dizziness9
- pain9
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 2 |
| 2009 | 9 |
| 2010 | 19 |
| 2011 | 12 |
| 2012 | 11 |
| 2013 | 6 |
| 2014 | 12 |
| 2015 | 19 |
| 2016 | 8 |
| 2017 | 18 |
| 2018 | 18 |
| 2019 | 12 |
| 2020 | 13 |
| 2021 | 10 |
| 2022 | 7 |
| 2023 | 6 |
| 2024 | 3 |
| 2025 | 7 |
| 2026 | 6 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Coartem (Artemether/Lumefantrine)
2024 spending
$83K
Beneficiaries
146
324 claims
Per beneficiary
$569
$5.59 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $75,008 |
| 2021 | $71,376 |
| 2022 | $65,905 |
| 2023 | $95,092 |
| 2024 | $83,102 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Artemether for severe malaria.
Esu EB, Effa EE, Opie ON, et al. · Cochrane Database Syst Rev 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Artemether for severe malaria.
Esu E, Effa EE, Opie ON, et al. · Cochrane Database Syst Rev 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Artemether-lumefantrine efficacy among adults on antiretroviral therapy in Malawi.
Nyangulu W, Mungwira RG, Divala TH, et al. · Malar J 2023 · Randomized Controlled Trial
- The gut-microbiome as a target for the treatment of schizophrenia: A systematic review and meta-analysis of randomised controlled trials of add-on strategies.
Minichino A, Brondino N, Solmi M, et al. · Schizophr Res 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Persistent and multiclonal malaria parasite dynamics despite extended artemether-lumefantrine treatment in children.
Goodwin J, Kajubi R, Wang K, et al. · Nat Commun 2024 · Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural
- Adjunctive ruxolitinib attenuates inflammation and enhances immunity in volunteers experimentally infected with Plasmodium falciparum.
Webster R, Oyong DA, Llewellyn S, et al. · Sci Transl Med 2025 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.